“We’ve been eagerly awaiting data from the first clinical trials of the Ebola virus vaccines and initial findings look promising. Prof Jonathan Ball, Professor of Molecular Virology, University of Nottingham, said: It’s important that this momentum is maintained and that these vaccines can move to being tested in countries affected by the epidemic as soon as possible.” We had more good news this week about another of these vaccines – rVSV-EBOV – with the announcement that Merck have struck a deal to scale up production and take it through clinical trials. It is why we and our international partners are supporting accelerated development of several vaccine candidates, including this one, at the same time. We need a variety of public health interventions if we are to impact on this and future outbreaks, and that must include vaccines. “This work is encouraging and another significant contribution to efforts to tackle the Ebola crisis. When we have these data in December it should be possible to decide on the most suitable dose to use and whether a booster dose will be needed in the West African efficacy trials”.ĭr Jeremy Farrar, Director of the Wellcome Trust, said: We will know about that vaccine soon as over 200 people have now been immunised. The immune responses reported suggest that the vaccine formulation to be used in West Africa should also be immunogenic. “These results on the safety of the chimpanzee adenovirus vaccine are very reassuring and the NIH team are to be congratulated on providing results so quickly. Prof Adrian Hill, Director of Jenner Institute, University of Oxford, and lead investigator of a UK safety trial of the GSK/NIH Ebola vaccine said: Researchers writing in the New England Journal of Medicine have discussed their finding from a phase I clinical trial using an Ebola vaccine derived from a chimpanzee adenovirus. The trial used twenty healthy adults, and the research group report no safety concerns. Expert reaction to preliminary results from phase I trial of chimpanzee adenovirus vector Ebola vaccine (cAd3-EBO)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |